Neurochemical studies of an analgesic, 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole [difenamizole]

T. Kameyama, Toshitaka Nabeshima, N. Yoshida, K. Yamaguchi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

For the purpose of clarifying the action mechanism of the analgesic agent, difenamazole (DFZ), chemically known as 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole, the following properties were investigated:-1) monoamine metabolizing enzymes, 2) biosynthesis of dopamine (DA), 3) binding of DA on the synaptic membrane of mice, 4) uptake of catecholamine (CA) by synaptosome in discrete brain areas and 5) DA release from the striatal slices of mice. Pertinent results obtained are delineated below: DFZ at 10-4 M inhibited the monoamine oxidase (MAO) activity to some extent although it had no activity on catechol-O-methyltransferase (COMT) at 10-6 -10-4 M. DZF significantly enhanced the DA accumulating activity of pargyline in the striatum. DFZ inhibited the binding of 3H-DA to synaptic membrane by 25% at 10-4 M in the striatum. DFZ inhibited the DA uptake by 50% at 10-4M though the activity was somewhat weaker than imipramine or cocaine on the striatum. DFZ inhibited the DA releae due to high K+ concentration in striatal slices at 10-4-5x10-4 M. From the above data, it was concluded r93w10 =and psoriasis rheumatism that DFZ may exert its analgesic effect by inhibiting the release of DA and preventing the binding of DA with the receptors.

Original languageEnglish
Pages (from-to)31-53
Number of pages23
JournalResearch Communications in Chemical Pathology and Pharmacology
Volume31
Issue number1
Publication statusPublished - 01-01-1981
Externally publishedYes

Fingerprint

Analgesics
Dopamine
Corpus Striatum
Synaptic Membranes
Pargyline
Catechol O-Methyltransferase
Membranes
difenamizole
diphenyl
pyrazole
Synaptosomes
Imipramine
Monoamine Oxidase
Dopamine Receptors
Rheumatic Diseases
Biosynthesis
Cocaine
Psoriasis
Catecholamines
Brain

All Science Journal Classification (ASJC) codes

  • Pathology and Forensic Medicine
  • Toxicology
  • Pharmacology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{963709c929e044cca1adb4326e411cb3,
title = "Neurochemical studies of an analgesic, 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole [difenamizole]",
abstract = "For the purpose of clarifying the action mechanism of the analgesic agent, difenamazole (DFZ), chemically known as 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole, the following properties were investigated:-1) monoamine metabolizing enzymes, 2) biosynthesis of dopamine (DA), 3) binding of DA on the synaptic membrane of mice, 4) uptake of catecholamine (CA) by synaptosome in discrete brain areas and 5) DA release from the striatal slices of mice. Pertinent results obtained are delineated below: DFZ at 10-4 M inhibited the monoamine oxidase (MAO) activity to some extent although it had no activity on catechol-O-methyltransferase (COMT) at 10-6 -10-4 M. DZF significantly enhanced the DA accumulating activity of pargyline in the striatum. DFZ inhibited the binding of 3H-DA to synaptic membrane by 25{\%} at 10-4 M in the striatum. DFZ inhibited the DA uptake by 50{\%} at 10-4M though the activity was somewhat weaker than imipramine or cocaine on the striatum. DFZ inhibited the DA releae due to high K+ concentration in striatal slices at 10-4-5x10-4 M. From the above data, it was concluded r93w10 =and psoriasis rheumatism that DFZ may exert its analgesic effect by inhibiting the release of DA and preventing the binding of DA with the receptors.",
author = "T. Kameyama and Toshitaka Nabeshima and N. Yoshida and K. Yamaguchi",
year = "1981",
month = "1",
day = "1",
language = "English",
volume = "31",
pages = "31--53",
journal = "Research Communications in Chemical Pathology and Pharmacology",
issn = "0034-5164",
publisher = "PJD Publications Ltd",
number = "1",

}

Neurochemical studies of an analgesic, 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole [difenamizole]. / Kameyama, T.; Nabeshima, Toshitaka; Yoshida, N.; Yamaguchi, K.

In: Research Communications in Chemical Pathology and Pharmacology, Vol. 31, No. 1, 01.01.1981, p. 31-53.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Neurochemical studies of an analgesic, 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole [difenamizole]

AU - Kameyama, T.

AU - Nabeshima, Toshitaka

AU - Yoshida, N.

AU - Yamaguchi, K.

PY - 1981/1/1

Y1 - 1981/1/1

N2 - For the purpose of clarifying the action mechanism of the analgesic agent, difenamazole (DFZ), chemically known as 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole, the following properties were investigated:-1) monoamine metabolizing enzymes, 2) biosynthesis of dopamine (DA), 3) binding of DA on the synaptic membrane of mice, 4) uptake of catecholamine (CA) by synaptosome in discrete brain areas and 5) DA release from the striatal slices of mice. Pertinent results obtained are delineated below: DFZ at 10-4 M inhibited the monoamine oxidase (MAO) activity to some extent although it had no activity on catechol-O-methyltransferase (COMT) at 10-6 -10-4 M. DZF significantly enhanced the DA accumulating activity of pargyline in the striatum. DFZ inhibited the binding of 3H-DA to synaptic membrane by 25% at 10-4 M in the striatum. DFZ inhibited the DA uptake by 50% at 10-4M though the activity was somewhat weaker than imipramine or cocaine on the striatum. DFZ inhibited the DA releae due to high K+ concentration in striatal slices at 10-4-5x10-4 M. From the above data, it was concluded r93w10 =and psoriasis rheumatism that DFZ may exert its analgesic effect by inhibiting the release of DA and preventing the binding of DA with the receptors.

AB - For the purpose of clarifying the action mechanism of the analgesic agent, difenamazole (DFZ), chemically known as 1,3-diphenyl-5-(2-dimethylaminopropionamide)-pyrazole, the following properties were investigated:-1) monoamine metabolizing enzymes, 2) biosynthesis of dopamine (DA), 3) binding of DA on the synaptic membrane of mice, 4) uptake of catecholamine (CA) by synaptosome in discrete brain areas and 5) DA release from the striatal slices of mice. Pertinent results obtained are delineated below: DFZ at 10-4 M inhibited the monoamine oxidase (MAO) activity to some extent although it had no activity on catechol-O-methyltransferase (COMT) at 10-6 -10-4 M. DZF significantly enhanced the DA accumulating activity of pargyline in the striatum. DFZ inhibited the binding of 3H-DA to synaptic membrane by 25% at 10-4 M in the striatum. DFZ inhibited the DA uptake by 50% at 10-4M though the activity was somewhat weaker than imipramine or cocaine on the striatum. DFZ inhibited the DA releae due to high K+ concentration in striatal slices at 10-4-5x10-4 M. From the above data, it was concluded r93w10 =and psoriasis rheumatism that DFZ may exert its analgesic effect by inhibiting the release of DA and preventing the binding of DA with the receptors.

UR - http://www.scopus.com/inward/record.url?scp=0019364224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0019364224&partnerID=8YFLogxK

M3 - Article

C2 - 6454942

AN - SCOPUS:0019364224

VL - 31

SP - 31

EP - 53

JO - Research Communications in Chemical Pathology and Pharmacology

JF - Research Communications in Chemical Pathology and Pharmacology

SN - 0034-5164

IS - 1

ER -